Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy

Abstract

Disseminated intravascular coagulation (DIC) is a complex and serious condition characterized by widespread activation of the coagulation cascade, resulting in both thrombosis and bleeding. This review aims to provide a comprehensive overview of DIC, emphasizing its clinical significance and the need for improved management strategies. We explore the primary causes of DIC, including sepsis, trauma, malignancies, and obstetric complications, which trigger an overactive coagulation response. At the molecular level, DIC is marked by excessive thrombin generation, leading to platelet and fibrinogen activation while simultaneously depleting clotting factors, creating a paradoxical bleeding tendency. Diagnosing DIC is challenging and relies on a combination of existing diagnostic criteria and laboratory tests. Treatment strategies focus on addressing the underlying causes and may involve supportive care, anticoagulation therapy, and other supportive measures. Recent advances in understanding the pathophysiology of DIC are paving the way for more targeted therapeutic approaches. This review highlights the critical need for ongoing research to enhance diagnostic accuracy and treatment efficacy, ultimately improving patient outcomes in those affected by DIC.

Keywords

coagulation / disseminated intravascular coagulation / fibrinolysis / sepsis / trauma

References

[1] Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. British journal of haematology. 2021; 192(5): 803-818.

[2] Gando S, Saitoh D, Ogura H, et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Critical Care (London, England). 2013; 17(3): R111.

[3] Wang B, Zhang B, Shen Y, Li J, Yuan X, Tang N. Validation of two revised, simplified criteria for assessing sepsis-associated disseminated intravascular coagulation in ICU patients with sepsis-3: a retrospective study. Laboratory medicine. 2023; 54(3): 291-298.

[4] Singh B, Hanson AC, Alhurani R, et al. Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004-2010): a population-based study. Chest. 2013; 143(5): 1235-1242.

[5] Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2018; 24(_suppl9): 8s-28s.

[6] Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Critical Care Medicine. 2004; 32(12): 2416-2421.

[7] Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Critical Care Medicine. 2008; 36(1): 145-150.

[8] Yamakawa K, Yoshimura J, Ito T, Hayakawa M, Hamasaki T, Fujimi S. External validation of the two newly proposed criteria for assessing coagulopathy in sepsis. Thrombosis and Haemostasis. 2019; 119(2): 203-212.

[9] Schmoch T, Möhnle P, Weigand MA, et al. The prevalence of sepsis-induced coagulopathy in patients with sepsis—a secondary analysis of two German multicenter randomized controlled trials. Annals of intensive care. 2023; 13(1): 3.

[10] Sun Y, Wang J, Wu X, et al. Validating the incidence of coagulopathy and disseminated intravascular coagulation in patients with traumatic brain injury–analysis of 242 cases. British Journal of Neurosurgery. 2011; 25(3): 363-368.

[11] Sawamura A, Hayakawa M, Gando S, et al. Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma. Thrombosis Research. 2009; 124(6): 706-710.

[12] Levi M. Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thrombosis research. 2018; 164(Suppl 1): S77-s81.

[13] Ten Cate H, Leader A. Management of disseminated intravascular coagulation in acute leukemias. Hamostaseologie. 2021; 41(2): 120-126.

[14] Erez O. Disseminated intravascular coagulation in pregnancy—Clinical phenotypes and diagnostic scores. Thrombosis research. 2017; 151(1): S56-S60.

[15] Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. Journal of thrombosis and haemostasis: JTH. 2013; 11(2): 223-233.

[16] Shahmarvand N, Oak JS, Cascio MJ, et al. A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. International journal of laboratory hematology. 2017; 39(4): 375-383.

[17] Paterno G, Palmieri R, Tesei C, et al. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia. Thrombosis research. 2024; 236: 30-36.

[18] Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Frontiers in oncology. 2022; 12: 1062524.

[19] Rattray DD, O’Connell CM, Baskett TF. Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009). Journal of Obstetrics and Gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2012; 34(4): 341-347.

[20] He L, Lin Q, Zhong L, Zeng Q, Song J. Thromboelastography maximum amplitude as an early predictor of disseminated intravascular coagulation in patients with heatstroke. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2022; 39(1): 605-610.

[21] Lin QW, Zhong LC, He LP, et al. A newly proposed heatstroke-induced coagulopathy score in patients with heat illness: a multicenter retrospective study in China. Chinese journal of traumatology = Zhonghua chuang shang za zhi. 2024; 27(2): 83-90.

[22] Hifumi T, Kondo Y, Shimazaki J, et al. Prognostic significance of disseminated intravascular coagulation in patients with heat stroke in a nationwide registry. Journal of critical care. 2018; 44: 306-311.

[23] Corbett B, Clark RF. North American snake envenomation. Emergency medicine clinics of North America. 2017; 35(2): 339-354.

[24] Moon JM, Chun BJ, Cho YS, et al. Coagulopathy after snake envenomation in South Korea. Clinical toxicology (Philadelphia, Pa). 2021; 59(10): 905-912.

[25] Gando S, Wada T. Disseminated intravascular coagulation in cardiac arrest and resuscitation. Journal of thrombosis and haemostasis: JTH. 2019; 17(8): 1205-1216.

[26] Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964; 202: 498-499.

[27] Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science (New York, NY). 1964; 145(3638): 1310-1312.

[28] Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. Journal of thrombosis and haemostasis: JTH. 2007; 5(6): 1106-1112.

[29] Hoffman M. A cell-based model of hemostasis. Thrombosis and haemostasis. 2001; 85(6): 958-965.

[30] Smith SA. The cell-based model of coagulation. Journal of veterinary emergency and critical care (San Antonio, Tex: 2001). 2009; 19(1): 3-10.

[31] Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood reviews. 2003; 17(Suppl1): S1-S5.

[32] Chandrabalan A, Ramachandran R. Molecular mechanisms regulating proteinase-activated receptors (PARs). The FEBS journal. 2021; 288(8): 2697-2726.

[33] Davie EW, Kulman JD. An overview of the structure and function of thrombin. Seminars in thrombosis and hemostasis. 2006; 32(Suppl1): 3-15.

[34] Hulshof AM, Hemker HC, Spronk HMH, Henskens YMC. Thrombin-fibrin(ogen) interactions, host defense and risk of thrombosis. International journal of molecular sciences. 2021; 22(5): 2590.

[35] Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Seminars in thrombosis and hemostasis. 2021; 47(7): 759-774.

[36] Al-Amer OM. The role of thrombin in haemostasis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2022; 33(3): 145-148.

[37] Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nature reviews Disease primers. 2016; 2: 16037.

[38] Wada T, Gando S. Phenotypes of disseminated intravascular coagulation. Thrombosis and haemostasis. 2024; 124(3): 181-191.

[39] Retter A, Hunt BJ. Consumptive coagulopathy in the ICU. Hematology American Society of Hematology Education Program. 2023; 2023(1): 754-760.

[40] Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nature reviews Disease Primers. 2021; 7(1): 30.

[41] Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018; 38(4): 709-725.

[42] De Palma R, Cirillo P, Ciccarelli G, et al. Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo: a possible contribution of immunity to thrombosis?. International journal of cardiology. 2016; 218: 188-195.

[43] Musgrave KM, Scott J, Sendama W, et al. Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis. Thrombosis research. 2023; 228: 10-20.

[44] Ito T. PAMPs and DAMPs as triggers for DIC. Journal of intensive care. 2014; 2(1): 67.

[45] Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagulation and cell signaling. Journal of thrombosis and haemostasis: JTH. 2018; 16(10): 1941-1952.

[46] Yang X, Cheng X, Tang Y, et al. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity. 2019; 51(6): 983-996.e986.

[47] Giustozzi M, Ehrlinder H, Bongiovanni D, et al. Coagulopathy and sepsis: pathophysiology, clinical manifestations and treatment. Blood reviews. 2021; 50: 100864.

[48] Levi M. Disseminated intravascular coagulation in cancer: an update. Seminars in thrombosis and hemostasis. 2019; 45(4): 342-347.

[49] Gould TJ, Lysov Z, Swystun LL, et al. Extracellular histones increase tissue factor activity and enhance thrombin generation by human blood monocytes. Shock (Augusta, Ga). 2016; 46(6): 655-662.

[50] Wu C, Lu W, Zhang Y, et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. 2019; 50(6): 1401-1411.e1404.

[51] Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends in cardiovascular medicine. 2016; 26(4): 297-303.

[52] Manoharan J, Rana R, Kuenze G, et al. Tissue factor binds to and inhibits interferon-α receptor 1 signaling. Immunity. 2024; 57(1): 68-85.e11.

[53] Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Critical care medicine. 2004; 32( Suppl5): S293-297.

[54] Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004; 103(4): 1342-1347.

[55] Hell L, Däullary T, Burghart V, et al. Extracellular vesicle-associated tissue factor activity in prostate cancer patients with disseminated intravascular coagulation. Cancers. 2021; 13(7): 1487.

[56] Liu S, Zhang Y, Zhao X, et al. Tumor-specific silencing of tissue factor suppresses metastasis and prevents cancer-associated hypercoagulability. Nano letters. 2019; 19(7): 4721-4730.

[57] Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Seminars in thrombosis and hemostasis. 2020; 46(3): 302-319.

[58] Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood reviews. 2021; 46: 100733.

[59] Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thrombosis and haemostasis. 2015; 113(4): 708-718.

[60] Laursen MA, Larsen JB, Hvas AM. Platelet function in disseminated intravascular coagulation: a systematic review. Platelets. 2018; 29(3): 238-248.

[61] Bester J, Matshailwe C, Pretorius E. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β IL-6 and IL-8. Cytokine. 2018; 110: 237-242.

[62] Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. The Journal of clinical investigation. 2003; 112(10): 1589-1596.

[63] Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-α and complement component 3 on coagulation. Scientific reports. 2018; 8(1): 1812.

[64] Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Critical care medicine. 2004; 32(5): 1136-1140.

[65] Liaw PC, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood reviews. 2016; 30(4): 257-261.

[66] de Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cellular & molecular immunology. 2019; 16(1): 19-27.

[67] Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. The Journal of clinical investigation. 2015; 125(12): 4638-4654.

[68] Stark K, Philippi V, Stockhausen S, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. 2016; 128(20): 2435-2449.

[69] Cai J, Lin Z. Correlation of blood high mobility group box-1 protein with mortality of patients with sepsis: a meta-analysis. Heart & lung: the journal of critical care. 2021; 50(6): 885-892.

[70] Wang Y, Fang C, Gao H, et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. The Journal of clinical investigation. 2014; 124(5): 2160-2171.

[71] Joshi A, Schmidt LE, Burnap SA, et al. Neutrophil-derived protein S100A8/A9 alters the platelet proteome in acute myocardial infarction and is associated with changes in platelet reactivity. Arteriosclerosis, thrombosis, and vascular biology. 2022; 42(1): 49-62.

[72] Colicchia M, Schrottmaier WC, Perrella G, et al. S100A8/A9 drives the formation of procoagulant platelets through GPIbα. Blood. 2022; 140(24): 2626-2643.

[73] Ryan TAJ, Preston RJS, O’Neill LAJ. Immunothrombosis and the molecular control of tissue factor by pyroptosis: prospects for new anticoagulants. The Biochemical journal. 2022; 479(6): 731-750.

[74] Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. The Journal of clinical investigation. 2020; 130(11): 6151-6157.

[75] Foley JH, Walton BL, Aleman MM, et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine. 2016; 5: 175-182.

[76] Conway EM. Complement-coagulation connections. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2018; 29(3): 243-251.

[77] Schrottmaier WC, Assinger A. The concept of thromboinflammation. Hamostaseologie. 2024; 44(1): 21-30.

[78] Papareddy P, Rydengård V, Pasupuleti M, et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS pathogens. 2010; 6(4): e1000857.

[79] Ekdahl KN, Teramura Y, Hamad OA, et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunological reviews. 2016; 274(1): 245-269.

[80] Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Seminars in thrombosis and hemostasis. 2008; 34(5): 459-468.

[81] Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. Journal of thrombosis and haemostasis: JTH. 2020; 18(12): 3142-3153.

[82] Rezaie AR, Giri H. Antithrombin: an anticoagulant, anti-inflammatory and antibacterial serpin. Journal of thrombosis and haemostasis: JTH. 2020; 18(3): 528-533.

[83] Ito T, Kakuuchi M, Maruyama I. Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. Critical care (London, England). 2021; 25(1): 95.

[84] Matsubara T, Yamakawa K, Umemura Y, et al. Significance of plasma fibrinogen level and antithrombin activity in sepsis: a multicenter cohort study using a cubic spline model. Thrombosis research. 2019; 181: 17-23.

[85] Beurskens DMH, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperger CP, Nicolaes GAF. The anticoagulant and nonanticoagulant properties of heparin. Thrombosis and haemostasis. 2020; 120(10): 1371-1383.

[86] Farrell DH, McConnell KM, Zilberman-Rudenko J, et al. Antithrombin III levels and outcomes among patients with trauma. JAMA network open. 2024; 7(8): e2427786.

[87] Watanabe-Kusunoki K, Nakazawa D, Ishizu A, Atsumi T. Thrombomodulin as a physiological modulator of intravascular injury. Frontiers in immunology. 2020; 11: 575890.

[88] Giri H, Biswas I, Rezaie AR. Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence. Journal of thrombosis and haemostasis: JTH. 2024; 22(4): 905-914.

[89] Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood. 2018; 132(2): 148-158.

[90] Oto J, Fernández-Pardo Á, Miralles M, et al. Activated protein C assays: a review. Clinica chimica acta; international journal of clinical chemistry. 2020; 502: 227-232.

[91] Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. Journal of thrombosis and haemostasis: JTH. 2013; 11 Suppl 1(0 1): 242-253.

[92] Esmon CT. The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Critical care (London, England). 2001; 5(2): S7-S12.

[93] Minhas N, Xue M, Fukudome K, Jackson CJ. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2010; 24(3): 873-881.

[94] Minhas N, Xue M, Jackson CJ. Activated protein C binds directly to Tie2: possible beneficial effects on endothelial barrier function. Cellular and molecular life sciences: CMLS. 2017; 74(10): 1895-1906.

[95] Birch CA, Wedegaertner H, Orduña-Castillo LB, Gonzalez Ramirez ML, Qin H, Trejo J. Endothelial APC/PAR1 distinctly regulates cytokine-induced pro-inflammatory VCAM-1 expression. Frontiers in molecular biosciences. 2023; 10: 1211597.

[96] Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. The Lancet Infectious diseases. 2012; 12(9): 678-686.

[97] Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Critical care medicine. 2003; 31(3): 834-840.

[98] Ahnström J, Petri A, Crawley JTB. Tissue factor pathway inhibitor—cofactor-dependent regulation of the initiation of coagulation. Current opinion in hematology. 2024; 31(6): 315-320.

[99] Van Den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. Journal of thrombosis and haemostasis: JTH. 2011; 9(1): 122-132.

[100] Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. Journal of thrombosis and haemostasis: JTH. 2015; 13(Suppl1): S98-105.

[101] Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Seminars in thrombosis and hemostasis. 2023; 49(3): 305-313.

[102] Sillen M, Declerck PJ. Thrombin activatable fibrinolysis inhibitor (TAFI): an updated narrative review. International journal of molecular sciences. 2021; 22(7): 3670.

[103] Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: the past, present, and future. Journal of thrombosis and haemostasis: JTH. 2019; 17(6): 852-862.

[104] Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Annals of intensive care. 2019; 9(1): 19.

[105] Hoshino K, Kitamura T, Nakamura Y, et al. Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis. Journal of intensive care. 2017; 5: 42.

[106] Tipoe TL, Wu WKK, Chung L, et al. Plasminogen activator inhibitor 1 for predicting sepsis severity and mortality outcomes: a systematic review and meta-analysis. Frontiers in immunology. 2018; 9: 1218.

[107] Wang P, Zhang Y, Yang H, et al. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands). 2018; 23(10): 756-764.

[108] David S, Mathews V. Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thrombosis research. 2018; 164(Suppl1): S82-S88.

[109] Bharadwaj AG, Holloway RW, Miller VA, Waisman DM. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers. 2021; 13(8): 1838.

[110] Neubauer K, Zieger B. Endothelial cells and coagulation. Cell and tissue research. 2022; 387(3): 391-398.

[111] Wang M, Hao H, Leeper NJ, Zhu L. Thrombotic regulation from the endothelial cell perspectives. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018; 38(6): e90-e95.

[112] Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. International Journal of Hematology. 2021; 113(1): 24-33.

[113] Asakura H, Takahashi H, Uchiyama T, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016; 14: 42.

[114] Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017; 15: 17.

[115] Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association. [Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017)]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2017; 38(5): 361-363.

[116] Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and haemostasis. 2001; 86(5): 1327-1330.

[117] Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ open. 2017; 7(9): e017046.

[118] Chen Y, Chen W, Ba F, et al. Prognostic accuracy of the different scoring systems for assessing coagulopathy in sepsis: a retrospective study. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2023; 29: 10760296231207630.

[119] Li J, Liu H, Wang N, et al. Persistent high sepsis-induced coagulopathy and sequential organ failure assessment scores can predict the 28-day mortality of patients with sepsis: a prospective study. BMC infectious diseases. 2024; 24(1): 282.

[120] Gigante B, Levy JH, van Gorp E, et al. Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. European Heart Journal. 2023; 44(32): 3040-3058.

[121] Yamakawa K, Umemura Y, Mochizuki K, et al. Proposal and Validation of a Clinically Relevant Modification of the Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Diagnostic Criteria for Sepsis. 2024.

[122] Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clinical Chemistry. 2016; 62(5): 699-707.

[123] Lundbech M, Krag AE, Christensen TD, Hvas AM. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. Thrombosis Research. 2020; 186: 80-85.

[124] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: a multi-center prospective observational study. Thrombosis Research. 2019; 173: 20-26.

[125] Larsen JB, Hvas AM. Fibrinolytic alterations in sepsis: biomarkers and future treatment targets. Seminars in Thrombosis and Hemostasis. 2021; 47(5): 589-600.

[126] Jackson Chornenki NL, Dwivedi DJ, Kwong AC, Zamir N, Fox-Robichaud AE, Liaw PC. Identification of hemostatic markers that define the pre-DIC state: a multi-center observational study. Journal of thrombosis and haemostasis: JTH. 2020; 18(10): 2524-2531.

[127] Schofield J, Abrams ST, Jenkins R, Lane S, Wang G, Toh CH. Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood advances. 2024; 8(10): 2499-2508.

[128] Hartmann J, Hermelin D, Levy JH. Viscoelastic testing: an illustrated review of technology and clinical applications. Research and practice in thrombosis and haemostasis. 2023; 7(1): 100031.

[129] Burton AG, Jandrey KE. Use of thromboelastography in clinical practice. The Veterinary clinics of North America Small animal practice. 2020; 50(6): 1397-1409.

[130] Haase N, Ostrowski SR, Wetterslev J, et al. Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive care medicine. 2015; 41(1): 77-85.

[131] Subramanian M, Kaplan LJ, Cannon JW. Thromboelastography-guided resuscitation of the trauma patient. JAMA surgery. 2019; 154(12): 1152-1153.

[132] Trevisan BM, Porada CD, Atala A, Almeida-Porada G. Microfluidic devices for studying coagulation biology. Seminars in cell & developmental biology. 2021; 112: 1-7.

[133] Chen Z, Lu J, Zhang C, et al. Microclot array elastometry for integrated measurement of thrombus formation and clot biomechanics under fluid shear. Nature communications. 2019; 10(1): 2051.

[134] Aithal S, Mishriki S, Gupta R, et al. SARS-CoV-2 detection with aptamer-functionalized gold nanoparticles. Talanta. 2022; 236: 122841.

[135] Wu H, Tang Y, Zhang B, et al. Miniaturized stacked transducer for intravascular sonothrombolysis with internal-illumination photoacoustic imaging guidance and clot characterization. IEEE transactions on bio-medical engineering. 2023; 70(8): 2279-2288.

[136] Yim W, Takemura K, Zhou J, et al. Enhanced photoacoustic detection of heparin in whole blood via melanin nanocapsules carrying molecular agents. ACS nano. 2022; 16(1): 683-693.

[137] Wang J, Chen F, Arconada-Alvarez SJ, et al. A nanoscale tool for photoacoustic-based measurements of clotting time and therapeutic drug monitoring of heparin. Nano letters. 2016; 16(10): 6265-6271.

[138] Liu M, Zaman K, Fortenberry YM. Overview of the therapeutic potential of aptamers targeting coagulation factors. International journal of molecular sciences. 2021; 22(8): 3897.

[139] Dickhout A, Van de Vijver P, Bitsch N, et al. Molecular detection of venous thrombosis in mouse models using SPECT/CT. Biomolecules. 2022; 12(6).

[140] Umemura Y, Okada N, Ogura H, Oda J, Fujimi S. A machine learning model for early and accurate prediction of overt disseminated intravascular coagulation before its progression to an overt stage. Research and practice in thrombosis and haemostasis. 2024; 8(5): 102519.

[141] Qin L, Mao J, Gao M, Xie J, Liang Z, Li X. Machine learning models can predict cancer-associated disseminated intravascular coagulation in critically ill colorectal cancer patients. Frontiers in pharmacology. 2024; 15: 1478342.

[142] Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2023; 81(5): 591-605.

[143] Leisring J, Brodsky SV, Parikh SV. Clinical evaluation and management of thrombotic microangiopathy. Arthritis & rheumatology (Hoboken, NJ). 2024; 76(2): 153-165.

[144] Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nature reviews Nephrology. 2021; 17(8): 543-553.

[145] Yamakawa K, Umemura Y, Murao S, Hayakawa M, Fujimi S. Optimal timing and early intervention with anticoagulant therapy for sepsis-induced disseminated intravascular coagulation. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2019; 25: 1076029619835055.

[146] Meziani F, Iba T, Levy JH, Helms J. Sepsis-induced coagulopathy: a matter of timeline. Intensive care medicine. 2024; 50(8): 1404-1405.

[147] Levi M, van der Poll T. Inflammation and coagulation. Critical care medicine. 2010; 38( Suppl2): S26-S34.

[148] Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama. 2001; 286(15): 1869-1878.

[149] Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of thrombosis and haemostasis: JTH. 2006; 4(1): 90-97.

[150] Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive care medicine. 2016; 42(4): 505-520.

[151] Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients. The Cochrane database of systematic reviews. 2016; 2(2): Cd005370.

[152] Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thrombosis research. 2013; 131(5): 383-389.

[153] Iba T. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan. Journal of thrombosis and haemostasis: JTH. 2013; 11(11): 2076-2078.

[154] Iba T, Saitoh D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical care (London, England). 2014; 18(5): 497.

[155] Hayakawa M, Yamakawa K, Kudo D, Ono K. Optimal antithrombin activity threshold for initiating antithrombin supplementation in patients with sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2018; 24(6): 874-883.

[156] Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Scientific reports. 2016; 6: 25984.

[157] Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Critical care medicine. 2015; 43(3): 511-518.

[158] Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Critical care (London, England). 2014; 18(5): 563.

[159] Tang Y, Wang X, Li Z, et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021; 54(3): 454-467.e456.

[160] Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA internal medicine. 2021; 181(12): 1612-1620.

[161] Squizzato A, Hunt BJ, Kinasewitz GT, et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thrombosis and haemostasis. 2016; 115(5): 896-904.

[162] Warkentin TE. Heparin-induced thrombocytopenia. Current Opinion in Critical Care. 2015; 21(6): 576-585.

[163] Warkentin TE. Platelet-activating anti-PF4 disorders: an overview. Seminars in hematology. 2022; 59(2): 59-71.

[164] May J, Westbrook B, Cuker A. Heparin-induced thrombocytopenia: an illustrated review. Research and practice in thrombosis and haemostasis. 2023; 7(5): 100283.

[165] Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. Journal of thrombosis and haemostasis: JTH. 2007; 5(1): 31-41.

[166] Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. Journal of thrombosis and haemostasis: JTH. 2015; 13(4): 508-519.

[167] Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. Jama. 2019; 321(20): 1993-2002.

[168] Levi M, Vincent JL, Tanaka K, et al. Effect of a recombinant human soluble thrombomodulin on baseline coagulation biomarker levels and mortality outcome in patients with sepsis-associated coagulopathy. Critical care medicine. 2020; 48(8): 1140-1147.

[169] Kato H, Hagihara M, Asai N, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation—A meta-analysis. Thrombosis research. 2023; 226: 165-172.

[170] Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Critical care medicine. 2003; 31(9): 2291-2301.

[171] Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England journal of medicine. 2001; 344(10): 699-709.

[172] Kylat RI, Ohlsson A. Recombinant human activated protein C for severe sepsis in neonates. The Cochrane database of systematic reviews. 2006;(2):Cd005385.

[173] Annane D, Timsit JF, Megarbane B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. American journal of respiratory and critical care medicine. 2013; 187(10): 1091-1097.

[174] de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000; 95(4): 1124-1129.

[175] Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical care medicine. 2001; 29(11): 2081-2089.

[176] Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Jama. 2003; 290(2): 238-247.

[177] Peng S, Xue G, Gong L, et al. A long-acting PAI-1 inhibitor reduces thrombus formation. Thrombosis and haemostasis. 2017; 117(7): 1338-1347.

[178] Wang D, Yang Y, Wang Y, et al. Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020; 130: 110528.

[179] Lucking AJ, Visvanathan A, Philippou H, et al. Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. Journal of thrombosis and haemostasis: JTH. 2010; 8(6): 1333-1339.

[180] Hirai T, Asano K, Ito I, et al. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Scientific reports. 2024; 14(1): 165.

[181] Akol H, Boon E, van Haren F, van der Hoeven J. Successful treatment of fulminant pneumococcal sepsis with recombinant tissue plasminogen activator. European journal of internal medicine. 2002; 13(6): 389.

[182] Suga Y, Tashiro K, Staub Y, et al. Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats. Thrombosis research. 2021; 206: 84-87.

[183] WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017; 389(10084): 2105-2116.

[184] Vlaar APJ. Blood transfusion: the search for the sweet spot. Intensive care medicine. 2022; 48(9): 1218-1221.

[185] Vlaar APJ, Dionne JC, de Bruin S, et al. Transfusion strategies in bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine. Intensive care medicine. 2021; 47(12): 1368-1392.

[186] Ryan TAJ, Hooftman A, Rehill AM, et al. Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress tissue factor in macrophages via inhibition of type i interferon. Nature communications. 2023; 14(1): 3513.

[187] Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019; 133(9): 906-918.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.